DPP4
Dipeptidyl peptidase 4
As of the edition of 20 October 2026, DPP4 (dipeptidyl peptidase 4, UniProt P27487) has 22 drugs tested at it and 31 companies on the list, 7 on route A and 7 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P27487
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 120
- Disease areas
- Nutrition and metabolism; Hormones; Pregnancy and women's health; Urinary and reproductive; Heart and blood vessels; Digestive system; Immune system; Cancer
- Registered trials of its drugs
- 928
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 10 |
| Active | 5 |
| Went quiet | 5 |
| Stopped | 2 |
| Total | 22 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sitagliptin | Marketed | Phase 4 | Ends 2026 |
| Vildagliptin | Marketed | Phase 4 | none listed |
| Linagliptin | Marketed | Phase 4 | Ends 2026 |
| Saxagliptin anhydrous | Marketed | Phase 4 | Ends 2027 |
| Alogliptin | Marketed | Phase 4 | Ends 2028 |
| Gemigliptin | Active | Phase 4 | none listed |
| Evogliptin | Marketed | Phase 4 | none listed |
| Teneligliptin | Marketed | Phase 4 | none listed |
| Trelagliptin | Marketed | Phase 4 | none listed |
| Omarigliptin | Marketed | Phase 4 | none listed |
| Retagliptin | Active | Phase 3 | none listed |
| DBPR-108 | Active | Phase 3 | none listed |
12 of 22 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Route B | 7 |
| Engaged | 8 |
| Undetermined | 9 |
| Total on the list | 31 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Boehringer Ingelheim | Route B |
| AstraZeneca | Route B |
The other 28 companies at DPP4
In the product31 companies in all; 28 are not named here, and no score is.
See the 31 companies at DPP4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.